To assess the advantages of moving from ligand binding assays (LBA) to microflow LC-MS/MS for large molecule bioanalysis and how the source design affects performance gains.
Contract Research Organization (CRO) specializing in pre-clinical and clinical LC-MS/MS and GC-MS/MS bioanalysis.
Development and validation of assays for the determination of therapeutic agents and biomarkers from biological matrices, supporting drug candidates from discovery through phase IV clinical trials.
Bioanalysis, method development and validation, and biomarker quantitation.